Crossref
Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer
Clinical Oncology · 2026-03 · 51 · 104018
DOI: 10.1016/j.clon.2025.104018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oncology, 2026-03. Verfasst von Mohamed Sheeraz Mohamed Azhar und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Azhar, M. S. M., Okuma, O., Owoseni, Y., Akala, O., Gul, R., Yassin, H., & Ayodele, O. (2026). Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer. Clinical Oncology, 51, 104018. https://doi.org/10.1016/j.clon.2025.104018
Vancouver
Azhar MSM, Okuma O, Owoseni Y, Akala O, Gul R, Yassin H, et al. Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer. Clinical Oncology. 2026;51:104018. doi:10.1016/j.clon.2025.104018
BibTeX
@article{Azhar2026,
author = {Azhar, Mohamed Sheeraz Mohamed and Okuma, Oghenevwede and Owoseni, Yetunde and Akala, Oyeyemi and Gul, Rabia and Yassin, Husam and Ayodele, Olubukola},
title = {Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer},
journal = {Clinical Oncology},
year = {2026},
volume = {51},
pages = {104018},
doi = {10.1016/j.clon.2025.104018}
}
EUVIMED